Advances in imaging (particularly prostate-specific membrane antigen [PSMA] PET and CT), molecular and genetic technologies, high-precision radiotherapy for curative treatment, and new therapies for advanced disease, along with the use of artificial intelligence (AI) tools, are likely to have an increasing role in detection and management of prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.